Clinical trial
Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for…
NCT00039000 · Agenus Inc., Industry · Completed
Key facts
| NCT number | NCT00039000 |
|---|---|
| Title | Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma |
| Official title | A Phase III Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus Physician's Choice Including Interleukin-2 and/or Dacarbazine/Temozolomide-based Therapy and/or Complete Tumor Resection in Stage IV Melanoma |
| Lead sponsor | Agenus Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Malignant Melanoma |
| Intervention type | Drug |
| Interventions | HSPPC-96 or Oncophage |
| Enrollment | 350 |
| Start date | Mar 1, 2002 |
| Primary completion | Dec 1, 2005 |
| Completion | Dec 1, 2005 |
| First posted | Jun 10, 2002 |
| Last update posted | Sep 7, 2012 |
| Countries | Australia, Hungary, Italy, Poland, Russia, Sweden, Ukraine, United Kingdom, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: